Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
- Written by PR Newswire
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today announced that the Blood published the latest results of its independently developed fully human...














